Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
148
Glucose Transporters01:27

Glucose Transporters

22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gain-of-function PfAAT1 mutations compensate for impaired PfCRT function in Plasmodium falciparum.

Research square·2026
Same author

Endoscopic Autologous Mucosal Transplantation (EAMT) for Management of Chronic Non-Healing Luminal Defects.

Gastrointestinal endoscopy·2026
Same author

Deciphering the temporal and spatial mutation dynamics of the SARS-CoV-2 spike glycoprotein.

Physical chemistry chemical physics : PCCP·2026
Same author

Mortality trends related to cardiac arrest in patients with diabetes mellitus aged 25 and older across the United States: an analysis using the CDC WONDER database from 1999 to 2024.

Archives of medical science : AMS·2026
Same author

Percutaneous Iatrogenic Atrial Septal Defect Closure Post Transcatheter Mitral Valve Repair: Revisiting MITHRAS Trial in a Larger Cohort.

Cureus·2026
Same author

Comment on "Prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study".

European journal of clinical pharmacology·2026
Same journal

2025 Scholars' Research Symposium Abstract: Influence of Disability Education, Panel Discussion on Comfort and Knowledge of Healthcare Providers in South Dakota.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Improving Interactions During Medical Interpretation: An Educational Module for Medical Students.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Walk With Ease Benefiting South Dakota.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Ultrasonographic Accuracy in Rural vs Urban Counties.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Minimizing Grief and Loss Through Advanced Care Planning.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
Same journal

2025 Scholars' Research Symposium Abstract: Food Security During Pregnancy and Adverse Birth Outcomes.

South Dakota medicine : the journal of the South Dakota State Medical Association·2025
See all related articles

Related Experiment Video

Updated: Jun 1, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

SGLT-2 Inhibitors: A Narrative Review.

Dawood Shehzad1, Muhammad Hasan1, Naveen Rajpurohit2

  • 1Internal Medicine Residency Program, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.

South Dakota Medicine : the Journal of the South Dakota State Medical Association
|January 17, 2025
PubMed
Summary
This summary is machine-generated.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer significant benefits beyond diabetes management, showing promise in treating cardiovascular and kidney diseases. Their expanding applications and increasing accessibility make them vital in modern medicine.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

182
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

Related Experiment Videos

Last Updated: Jun 1, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

182
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiology
  • Nephrology
  • Oncology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for glycemic control in type 2 diabetes.
  • Emerging evidence highlights their pleiotropic effects extending beyond glucose lowering.
  • These effects have significant implications for cardiovascular and renal health.

Purpose of the Study:

  • To review the expanded therapeutic applications of SGLT2 inhibitors.
  • To discuss their established and potential benefits in various non-diabetic conditions.
  • To consider the implications of their broader use and accessibility.

Main Methods:

  • Comprehensive literature review of clinical trials and observational studies.
  • Analysis of pharmacological mechanisms underlying SGLT2 inhibitor action.
  • Evaluation of data on cardiovascular, renal, and oncological outcomes.

Main Results:

  • SGLT2 inhibitors demonstrate robust efficacy in reducing cardiovascular events and slowing the progression of chronic kidney disease.
  • Evidence suggests potential benefits in managing hypertension and exploring applications in cancer therapy.
  • Adverse effects and contraindications are noted but generally manageable.

Conclusions:

  • SGLT2 inhibitors represent a significant therapeutic advancement with broad applications beyond diabetes.
  • Their cardiovascular and renal protective effects are well-established, with emerging roles in other diseases.
  • Increased accessibility through generic availability promises wider patient benefit.